CAE Healthcare

caehealthcare.com

CAE Healthcare: Providing solutions for simulation-based medical education (SBME) that improve healthcare, clinical competency, and patient CAE Healthcare delivers advanced, state-of-the-art simulation-based training that enables healthcare professionals to provide safer, high-quality care. Our end-to-end spectrum of solutions include patient, imaging, interventional and surgical simulation, audiovisual solutions, learning applications, and center management programs to drive the future of innovation in training for the benefit of patients and healthcare providers the world over.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

news image

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More

BUSINESS INSIGHTS

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

news image

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More

PHARMACY MARKET

IONIS AND ASTRAZENECA CLOSE DEAL TO DEVELOP AND COMMERCIALIZE EPLONTERSEN

Ionis Pharmaceuticals, Inc. | December 30, 2021

news image

Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthy...

Read More

PHARMACY MARKET

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

news image

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More
news image

PHARMA TECH

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More
news image

BUSINESS INSIGHTS

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More
news image

PHARMACY MARKET

IONIS AND ASTRAZENECA CLOSE DEAL TO DEVELOP AND COMMERCIALIZE EPLONTERSEN

Ionis Pharmaceuticals, Inc. | December 30, 2021

Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthy...

Read More
news image

PHARMACY MARKET

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More